10 research outputs found
The contributions of James Lyke to piano pedagogy
No full textJames Lyke’s career spans more than 40 years as an educator, author, administrator, composer, clinician, adjudicator, and performer. His cutting-edge teaching materials and numerous domestic and international workshops affected thousands of piano instructors and students worldwide. While co-founding the National Conference on Piano Pedagogy, Lyke also served as a professor at the University of Illinois. The purpose of this study is to document James Lyke’s contributions to the field of piano pedagogy. Despite Lyke’s timeless endeavors as one of the most distinguished piano pedagogues of this modern era, there has been no research to date which attempts to evaluate his career. The investigation of his accomplishments enhances the understanding of contemporary piano pedagogy.
This research comprises seven sections. Chapter 1 provides an introduction, statement of the problem, need for study, and five research questions. Chapter 2 discusses related studies. Chapter 3 introduces the methodology used and reveals the results of three interviews and 30 surveys from colleagues and students retrieved both online and via mail. Chapter 4 reveals the life of Lyke through a biographical approach, and Chapter 5 examines his professional activities as professor at the University of Illinois and his versatile career as an organizational leader, performer, and clinician. Lyke’s contributions through publications are evaluated in Chapter 6, and Chapter 7 concludes the study by summarizing answers to the research questions posed in Chapter 1 and providing recommendations for further study. Appendixes comprise selective lists of awards, workshops, performances, the consent letter, and the questionnaire for the interview and survey, including screenshots of the online survey. His professional contributions examined through multiple viewpoints illustrate the impact of Lyke in advancing the field of piano pedagogy, and depict Lyke’s exemplary career as a pedagogue.Item withdrawn by Mark Zulauf ([email protected]) on 2012-02-27T15:06:58Z
Item was in collections:
University of Illinois Theses & Dissertations (ID: 1)
No. of bitstreams: 1
Choi_CheeHyeon.pdf: 1718548 bytes, checksum: 6100c7972a90999d7ae5ed87a8c067ed (MD5)Made available in DSpace on 2012-05-22T00:31:13Z (GMT). No. of bitstreams: 2
Choi_CheeHyeon.pdf: 26920497 bytes, checksum: 7267fc35021abed97f9bf5af662a08e3 (MD5)
license.txt: 4058 bytes, checksum: d6feb25db0bd4eb213b5c9bc2ba099f7 (MD5
Catering Group Piano Curriculum for the Music Educators of the Next Generation
No full textAdvances in consumer technology have drastically changed the ways students access and appreciate music. As a result, teaching materials in group piano curriculum have become quickly outdated. Students no longer recognize folk tunes that have been sung or used for harmonization exercises; they prefer to listen and play music on their playlist stored in their mobile devices. Although pedagogical principles and objectives should persist over time, teaching methodologies and materials should continuously be updated to increase students’ engagement in learning. The newer generation of students favor classes that are more practical, satisfy their personal interests, and meet their degree program expectations.
Since education majors require keyboard proficiency, group piano programs play a critical role in their learning. Collegiate group piano classes can be a steppingstone for cultivating a wider range of audiences by utilizing instructional technology. Empowering these students with innovative keyboard skill curricula ultimately delivers positive results to the future generation. Integration of technology and innovative class projects help create engaging class sessions that actively draw learners’ participation, enable deeper learning, and gain strategies to apply in their future teaching career
Influence of C<sub>2</sub>F<sub>6</sub>Addition to Cl<sub>2</sub>/Ar Gas on Nanometer-Scale Etch Characteristics of TiN Thin Films Using Inductively Coupled Plasma
No full text
Development of a Local-Scale Spatially Refined Multimedia Fate Model (LSRMFM) for Urban-Scale Risk Assessment: Model Formulation, GIS-Based Preprocessing, and Case Study
No full textErratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
No full textnon present
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.
No full textBACKGROUND
Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited.
METHODS
In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year. The principal secondary outcome was target-lesion failure, an effectiveness composite of death from cardiac causes, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. Both outcomes were powered for noninferiority.
RESULTS
A total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drug-coated stents (993 patients). At 1 year, the primary outcome was observed in 169 of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 (16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; noninferiority margin, 4.4; P = 0.007 for noninferiority).
CONCLUSIONS
Among patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes. (Funded by Medtronic; ONYX ONE ClinicalTrials.gov number, NCT03344653.)
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
No full textZhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. LANCET. 2021;398(10304):957-980.Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier
